Low Molecular Weight Heparins as Antineoplastic Agents

Author(s): Sergio Siragusa

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 3 , Issue 3 , 2008

Become EABM
Become Reviewer
Call for Editor


There is an increasing interest in the potential role of low molecular weight heparins (LMWHs) in the management of cancer patients. These antithrombotic agents have generated particular excitement because they have been proved useful in both the prevention and treatment of venous thromboembolism (VTE) in patients with malignancy. Recent reports are, at the same time, highlighting a potential role of LMWHs on patient survival due to their presumed antineoplastic action. This review will discuss the most recent reports and patents on these topics.

Keywords: Low molecular weight heparins (LMWH), antithrombotic agents, antitumor therapy, venous thromboembolism (VTE)

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Published on: 01 March, 2012
Page: [159 - 161]
Pages: 3
DOI: 10.2174/157489208786242287
Price: $65

Article Metrics

PDF: 1